Calcific uremic arteriolopathy (calciphylaxis) - Case series and review of clinical features and terminology

被引:1
作者
Rickels, Michael R.
Junkins-Hopkins, Jacqueline M.
Metkus, Thomas S.
Iqbal, Nayyar
机构
[1] Univ Penn, Sch Med, Dept Med, Div Endocrinol Diabet & Metab, Philadelphia, PA 19104 USA
[2] Univ Penn, Sch Med, Dept Dermatol, Div Dermatopathol, Philadelphia, PA 19104 USA
[3] Philadelphia Vet Adm Med Ctr, Dept Med, Philadelphia, PA USA
关键词
cutaneous ulceration; chronic kidney disease; calcium phosphorus product; hyperparathyroidism;
D O I
10.1097/01.ten.0000255808.25351.45
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We present 3 cases of calciphylaxis, better termed calcific uremic arteriolopathy (CUA), which illustrate typical and atypical presentations of this disorder to discuss its classification, pathophysiology, and treatment based on a review of the literature. Of the 3 patients presenting with biopsy-proven CUA, 1 patient with proximal lesions expired in the setting of upper gastrointestinal bleeding and superinfection of ulcers, a second patient had an extensive distal ulcerative lesion that failed to heal and necessitated lower-extremity amputation, and a third patient with multiple small distal lesions experienced complete resolution of the ulcers. The classification, pathophysiology, and treatment of CUA are detailed here. CUA is a heteroaeneous syndrome which typically follows a progressive course leading to loss of life or limb. Diagnosis requires a high index of suspicion and low threshold for biopsy in at-risk patients. Parathyroidectomy is appropriate to rapidly lower the calcium-phosphorus product in the setting of marked hyperparathyroidism; additional therapy includes the avoidance of purported precipitants, medical lowering of the serum calcium and phosphorus, and promotion of wound healing with hyperbaric oxygen therapy.
引用
收藏
页码:57 / 62
页数:6
相关论文
共 44 条
[1]   Calciphylaxis is associated with hyperphosphatemia and increased osteopontin expression by vascular smooth muscle cells [J].
Ahmed, S ;
O'Neill, KD ;
Hood, AF ;
Evan, AP ;
Moe, SM .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2001, 37 (06) :1267-1276
[2]  
Alves D, 2002, HOSP PHYS, V38, P39
[3]   Therapy for calciphylaxis: An outcome analysis [J].
Arch-Ferrer, JE ;
Beenken, SW ;
Rue, LW ;
Bland, KI ;
Diethelm, AG .
SURGERY, 2003, 134 (06) :941-944
[4]   Clinical practice guidelines for bone metabolism and disease in chronic kidney disease: An overview [J].
Bailie, GR ;
Massry, SG .
PHARMACOTHERAPY, 2005, 25 (12) :1687-1707
[5]   A 70-year-old woman with end-stage renal disease and cutaneous ulcers - Uremic small-artery disease with medial calcification and intimal hyperplasia (calciphylaxis) [J].
Baran, DT ;
Letts, GS ;
McClaud, TC ;
Mackool, BT ;
Colvin, RB ;
Kronenberg, HM .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (15) :1119-1124
[6]  
BARGMAN JM, 1995, J RHEUMATOL, V22, P5
[7]  
Basile C, 2002, J NEPHROL, V15, P676
[8]   A case control study of proximal calciphylaxis [J].
Bleyer, AJ ;
Choi, M ;
Igwemezie, B ;
de la Torre, E ;
White, WL .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 32 (03) :376-383
[9]   Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis [J].
Block, GA ;
Martin, KJ ;
de Francisco, ALM ;
Turner, SA ;
Avram, MM ;
Suranyi, MG ;
Hercz, G ;
Cunningham, J ;
Abu-Alfa, AK ;
Messa, P ;
Coyne, DW ;
Locatelli, F ;
Cohen, RM ;
Evenepoel, P ;
Moe, SM ;
Fournier, A ;
Braun, J ;
McCary, LC ;
Zani, VJ ;
Olson, KA ;
Drüeke, TB ;
Goodman, WG .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (15) :1516-1525
[10]  
Braden G, 1997, J AM SOC NEPHROL, V8, pA2556